Results 141 to 150 of about 221,174 (192)

Rationally designed minimized TbpB confers broad protection against meningococcal infection. [PDF]

PLoS Pathog
Islam EA, Fegan JE, Cole GB, Calmettes C, Ng D, Au NYT, Marion C, Ahn SK, Curran DM, Caruso LL, Schryvers AB, Moraes TF, Gray-Owen SD.   +12 more
europepmc   +1 more source

Adherence to recommended immunization schedule during adolescence: findings of a cross-sectional study in the Southern part of Italy. [PDF]

BMC Public Health
Licata F, Scicchitano CA, Ficara F, Di Gennaro G, Bianco A.   +4 more
europepmc   +1 more source

Life Course Vaccination Continuum (LCVAC): An Expert Consensus on Life Course Vaccination in India. [PDF]

Cureus
Koul PA, Vora A, Tiwaskar M, Bhargava R, Dhar R, Ramasubramanian VR, Kher V, Nangia V, Jha V, Dutta T, Mahajan M.   +10 more
europepmc   +1 more source

"Why should I pay for this vaccine?" - Norwegian adolescents views on meningococcal vaccination. [PDF]

BMC Public Health
Gleditsch RN, Watle SV, Hansen BT, Naess LM, Juvet LK, Ofitserova TS.   +5 more
europepmc   +1 more source

Persistence of Serum Bactericidal Antibody in the First 2-Years After Immunization with Pentavalent Meningococcal ACWYX Vaccine in Malian Infants and Toddlers. [PDF]

Clin Infect Dis
Chen WH, Haidara FC, Diallo F, Tapia MD, Hubbard FA, Alderson MR, Hausdorff WP, Martellet L, Hosken N, Kapse D, Kulkarni PS, Townsend-Payne K, Borrow R, Posavad CM, Kelly CW, Mercer LD, Sow SO, Kotloff KL.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Meningococcal Vaccines

Infectious Disease Clinics of North America, 2001
Global control and prevention of meningococcal disease depends on the further development of vaccines that overcome the limitations of the current polysaccharide vaccines. Protein-polysaccharide conjugate vaccines likely will address the marginal protective antibody responses and short duration of immunity in young children derived from the A, C, Y ...
N E, Rosenstein, M, Fischer, J W, Tappero   +2 more
openaire   +2 more sources

Review of meningococcal vaccines with updates on immunization in adults [PDF]

Human Vaccines and Immunotherapeutics, 2014
Meningococcal disease is a serious and global life-threatening disease. Six serogroups (A, B, C, W-135, X, and Y) account for the majority of meningococcal disease worldwide.
Ghassan Dbaibo
exaly   +2 more sources

Meningococcal carriage, meningococcal disease and vaccination

Journal of Infection, 1988
Group A meningococcal carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine in a rural area of The Gambia. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%)
M K, Hassan-King, R A, Wall, B M, Greenwood   +2 more
openaire   +2 more sources